In this study the investigators will study the effects of neoadjuvant radiation therapy (RT), in the form of either proton therapy or stereotactic body radiation therapy (SBRT), on the Circulating tumor DNA (ctDNA), radiographic changes and radiomics, and the validity of these findings will be compared using the current gold standard- pathologic findings. The purpose of this work is to explore whether the biomarkers may be used diagnostically to better understand radiographic changes following RT. The investigators hypothesize that ctDNA levels in combination with imaging biomarkers identified through radiomics will be a sensitive and specific tool for predicting histopathologic response to RT.
Study Type
OBSERVATIONAL
Enrollment
40
the effects of neoadjuvant RT, in the form of either proton therapy or SBRT, on the ctDNA
Johns Hopkins Hospital
Baltimore, Maryland, United States
RECRUITINGUniversity of Pennsylvania
Philadelphia, Pennsylvania, United States
RECRUITINGSensitivity and specificity of combining ctDNA and radiomics
Sensitivity and specificity of combining ctDNA and radiomic features in predicting histopathologic changes at surgery defined by patients who have \<10% necrosis, the percentage of patients who are deemed "positive" by the model based on ctDNA and radiomics
Time frame: within one week after surgery
Percent of necrotic and active tumor cells
Percent of necrotic and active tumor cells following neoadjuvant RT using proton therapy or SBRT according to the Johns Hopkins Solid Tumor Panel Next Generation Sequencing
Time frame: within one week after surgery
Change in plasma ctDNA levels
Change in plasma ctDNA levels following neoadjuvant RT for spinal chordoma and correlate changes in ctDNA levels with histopathologic changes at surgery
Time frame: within one week after surgery
Correlate radiomic features with histopathologic and genomic features
Correlate radiomic features with histopathologic and genomic features in patients receiving neoadjuvant RT for spinal and sacral chordoma
Time frame: within one week after surgery
Radiographic local recurrence
Radiographic local recurrence defined as evidence of progressive disease on CT/MRI in the operative site when compared to post-op imaging.
Time frame: within one week after surgery
Rate of wound healing complications
Rate of wound healing complications following neoadjuvant RT for spinal chordoma
Time frame: within one week after surgery
Health related quality of life as assessed by the European Organization for Research and Treatment of Cancer (EORTC) quality of life (QLQ-C15-PAL) questionnaire
Health related quality of life following neoadjuvant RT for spinal chordoma measured by the European Organization for Research and Treatment of Cancer (EORTC) quality of life (QLQ-C15-PAL) questionnaire. The scoring ranges from 0-21, with 21 being the highest quality of life.
Time frame: within one week after surgery
Local progression free survival
Local progression free survival following neoadjuvant RT for spinal chordoma
Time frame: 3 years
Overall survival
Overall survival following neoadjuvant RT for spinal chordoma
Time frame: 3 years
Relationship between ctDNA post-op and local Progression Free Survival (PFS)
The relationship between circulating tumor DNA post-operatively and local PFS following neoadjuvant RT for spinal chordoma
Time frame: 3 years
Relationship between ctDNA post-op and Overall Survival (OS)
The relationship between circulating tumor DNA post-operatively and OS following neoadjuvant RT for spinal chordoma
Time frame: 3 years
Toxicity of neoadjuvant RT as assessed by CTCAE version 5
Toxicity of neoadjuvant RT for chordoma using CTCAE version 5
Time frame: 3 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.